Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

ABSTRACT

Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults. Commercial arrangement There is a simple discount patient access scheme for olaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact Market.AccessUK@astrazeneca.com for details.